Variants in the ADGRL3 gene affect how individuals respond to ADHD medications such as methylphenidate and atomoxetine, influencing their metabolism and therapeutic outcomes. This gene also has potential implications for the response to other substances like amphetamine and nicotine, possibly affecting addiction and behavioral responses through its role in neuronal interactions.